

Technical Advisory Group on the Global Elimination of Lymphatic Filariasis (TAG-ELF)

*Report of the Fifth Meeting
Geneva, Switzerland
3–6 February 2004*



World Health
Organization

© World Health Organization, 2004

All rights reserved.

This health information product is intended for a restricted audience only. It may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means.

The designations employed and the presentation of the material in this health information product do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

The World Health Organization does not warrant that the information contained in this health information product is complete and correct and shall not be liable for any damages incurred as a result of its use.

**TECHNICAL ADVISORY GROUP ON
THE GLOBAL ELIMINATION OF
LYMPHATIC FILARIASIS**

**Report of the Fifth Meeting
World Health Organization, Geneva, Switzerland
3 – 6 February 2004**

Members:

Dr D. Addiss (USA), *Rapporteur*
Dr R. Baru (India)
Dr M. Bockarie (Sierra Leone)
Dr K.Y. Dadzie (Ghana), *Chairman*
Dr J. Gyapong (Ghana)
Dr J. Habbema (Netherlands)
Dr R.H. Henderson (USA)
Dr L.M. Hernandez (Philippines)
Professor M.M. Ismail (Sri Lanka)
Dr H.A. Kamal (Egypt)
Dr D. Kyelem (Burkina Faso)
Dr S. Persaud (Guyana)
Professor Dato Dr C.P. Ramachandran (Malaysia)
Dr J. Sokhey (India)

Contents

	Page
1. Opening and introduction	9
2. Global Programme to Eliminate Lymphatic Filariasis – update.....	9
2.1 Mapping and scaling up of mass drug administration	9
2.2 Drug procurement	11
2.3 Disability prevention, social mobilization, training and capacity building.....	11
2.4 Follow-up of previous TAG-ELF recommendations	12
2.5 Regional Programme Review Group updates	12
2.6 Report of the Chair, Task Force for Communications, Global Alliance to Eliminate Lymphatic Filariasis (GAELF)	13
2.7 Update on Informal Consultation on Fundraising for Lymphatic Filariasis (LF) in Africa.....	14
2.8 Report of the Chairman, TAG-ELF	14
3. Monitoring and evaluation issues	14
3.1 Report of the monitoring and evaluation working group	14
3.2 Field module on monitoring PELF	15
3.3 Use of simulation models in programmatic decisions – status of tools available, potential areas of use, and their limitations	15
3.4 Indicators for monitoring disability prevention	16
4. Chemotherapy	16
4.1 Impact of mass drug co-administration on reducing microfilaraemia	16
4.2 Age groups that escape treatment with chemotherapy because they are under 90 cm tall.....	17
4.3 Benefit of chemotherapy in the 1–5-year age group.....	18
4.4 Risk–benefit of co-administered drugs versus single drugs.....	18
4.5 Chemotherapy of individual microfilaria carriers	19
4.6 Updates on issues related to chemotherapy in Loa loa co-endemic areas	19
5. When to stop MDA: monitoring criteria proposed by the Pacific Initiative for the Elimination of Lymphatic Filariasis	20

6. Pharmacovigilance on MDA with co-administered drugs.....	21
7. Research – report on the Lymphatic Filariasis Research Forum.....	21
8. Results of completed, ongoing and future WHO/World Bank/UNDP Special Programme for Research and Training (TDR) research areas	22
9. Issues related to meeting the challenge of scaling up MDA to 350 million by 2005.....	23
10. Strategies for implementing prevention of disability caused by LF	23
11. Elements for effective social mobilization and communication for achieving high drug coverage and needs for GPELF	24
12. Regional operational issues and proposed operational research studies for finding locally relevant solutions	24
13. Future working arrangements for TAG-ELF	25
14. Conclusions and recommendations	25
14.1 General.....	25
14.2 Monitoring and evaluation	26
14.2.1 Epidemiological modelling	26
14.2.2 Monitoring and evaluation –working group report	26
14.2.3 PacELF.....	27
14.2.4 Verifying absence of transmission.....	27
14.3 Chemotherapy.....	27
14.3.1 Treatment of young children	28
14.3.2 Chemotherapy for individual microfilaria carriers	28
14.3.3 Safety	28
14.4 Strategic issues regarding scaling up of GPELF	28
14.4.1 Programme synergy	29
14.4.2 Loa loa.....	29
14.5 Social mobilization	29
14.6 Disability prevention.....	30
14.7 Research.....	30

Annex 1 List of participants 31

Annex 2 Agenda..... 35

**Annex 3 Summary of report submitted to the Technical Advisory Group for
filariasis WHO, Geneva, January 2004 37**

1. Opening and introduction

The Fifth Meeting of the Technical Advisory Group on the Global Elimination of Lymphatic Filariasis (TAG-ELF) was held in the headquarters of the World Health Organization (WHO), Geneva, Switzerland, from 3 to 6 February 2004. The meeting was opened by Dr H. Endo, Director, Department of Control, Prevention, and Eradication (CPE) of the Communicable Diseases Cluster. Dr Endo welcomed all the participants and thanked TAG-ELF members for contributing their time and expertise. He pointed out that the meeting was particularly critical because of the financial crisis affecting WHO and the Global Programme to Eliminate Lymphatic Filariasis (GPELF).

The meeting was attended by all 14 members of TAG-ELF. Other participants were members of the WHO Secretariat, staff of the WHO Regional Offices for Africa, the Americas, the Eastern Mediterranean, South-East Asia, and the Western Pacific, technical experts to advise TAG-ELF on specific issues, and observers from the Global Alliance to Eliminate Lymphatic Filariasis (GAELF). Dr K.Y. Dadzie continued to serve as Chairman and Dr D. Addiss was appointed Rapporteur. Dr Dadzie welcomed the participants and introduced two new TAG-ELF members – Professor Dato Dr C.P. Ramachandran (Malaysia) and Dr Addiss (USA). A full list of participants is given in Annex 1.

Dr Dadzie suggested minor rescheduling of the agenda. Dr Ramachandran moved to accept the revised agenda and this was seconded by Dr R. Henderson. The agenda adopted is given in Annex 2.

Dr Henderson pointed out that the financial crisis affecting WHO was also felt by the filariasis elimination programmes at country level, and suggested that “packaging” lymphatic filariasis (LF) elimination with programmes for the control of other parasitic diseases, such as intestinal helminths, might have advantages. Dr Dadzie agreed and indicated that this issue would be addressed on the agenda.

2. Global Programme to Eliminate Lymphatic Filariasis – update

Drs G. Biswas, F. Rio, and S. Yactayo reported on progress made by the Global Programme to Eliminate Lymphatic Filariasis (GPELF) since the previous TAG-ELF meeting in March 2003. Their reports included updates on mapping, mass drug administration (MDA), drug procurement, disability prevention, social mobilization, and training and capacity building

2.1 Mapping and scaling up of mass drug administration

A total of 83 countries are now considered LF-endemic, including three that have been added to the list since the previous TAG-ELF meeting, namely the Marshall Islands, Palau and Timor-Leste. Four countries that have been considered LF-endemic but in which surveys have not detected infected persons or, in some cases, infected mosquitoes, have been included in the list: they are Costa Rica, Solomon Islands, Suriname, and Trinidad and Tobago.

Of the 83 LF-endemic countries, 45 have completed mapping. Mapping is currently in progress in 18 countries and is planned in nine others (see Table 1). In the remaining 11 countries, plans for mapping have not yet been formulated. The current version of the immuno-chromatographic card test (ICT) requires that it be read at 10 minutes. During 2003, 107 000 ICT cards were procured by WHO for mapping and were provided to endemic countries. The manufacturer, Binax, has raised the cost of the cards to US\$ 2.20 each, based

on a minimum guaranteed purchase of 200 000 cards per year. It is difficult for WHO to guarantee the purchase of this number, as funds are currently limited.

Table 1. Progress in mapping of LF distribution by regional PRG in 2003

Region	Completed	In progress	Planned	Outstanding	No. of countries
Africa	13	8	8	10	39
Americas	5	2	0	0	7
Eastern Mediterranean	2	0	1	0	3
Mekong-Plus	7	4	0	1	12
Indian Subcontinent	2	3	0	0	5
PacELF	16	1	0	0	17
Total	45	18	9	11	83

By the end of 2003, a total of 38 countries were implementing MDA. During the course of that year, about 81 million people received two-drug combinations of either albendazole plus diethylcarbamazine citrate (DEC) or albendazole plus ivermectin, and 52 million received DEC alone; this total coverage of approximately 133 million people is a remarkable achievement (see Tables 2 and 3). However, the at-risk population in these 83 endemic countries is approximately 1.3 billion, meaning that only 6.5% of the total at-risk population have participated in MDA. One country has completed five rounds of MDA, implementation units (IUs) in 11 countries have completed four, and another 11 countries have completed three rounds.

Table 2. Progress of MDA with co-administrated drugs in 2003

Region	No. of endemic countries	At-risk pop. in millions	% of global burden	No. of countries started MDA	At-risk pop. covered in 2003 in millions	% of at-risk pop. covered in 2002
Africa	39	477	37.9	9	23.6	4.95
Americas	7	9	0.7	3	1.9	21.11
Eastern Mediterranean	3	29	2.3	2	2.6	8.97
Mekong-Plus	12	214	17	6	22.5	10.51
Indian Subcontinent ^a	5	524	41.6	4	28.6	5.46
PacELF	17	6	0.5	14	2.2	36.67

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_30127

